| 
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.  | 
|   | 
 | 
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Roche/Genentech  | 
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst)  | 
Travel, Accommodations, Expenses - AstraZeneca; celgene; Novartis  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Consulting or Advisory Role - AstraZeneca; Eisai; Merck  | 
Travel, Accommodations, Expenses - Celgene; Novartis; Roche  | 
|   | 
 | 
Travel, Accommodations, Expenses - Roche  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Honoraria - Novartis; Roche  | 
Consulting or Advisory Role - Novartis; Roche  | 
Travel, Accommodations, Expenses - Novartis; Roche  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Honoraria - Celgene; Eisai  | 
Research Funding - Celgene (Inst)  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Honoraria - Amgen; Eisai; Pierre Fabre; Teva  | 
Travel, Accommodations, Expenses - Pierre Fabre; Roche; Teva  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Consulting or Advisory Role - Eisai  | 
Speakers' Bureau - Celgene; Eisai; Novartis  | 
Research Funding - AstraZeneca (Inst); Bayer (Inst); Macrogenics (Inst); Pfizer (Inst); Roche (Inst)  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Consulting or Advisory Role - AstraZeneca; Novartis; Roche  | 
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)  | 
Travel, Accommodations, Expenses - AstraZeneca; Celgene  |